The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells
The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells. C B Verchere , D A D'Alessio , R L Prigeon , R L Hull and S E Kahn Department of Medicine, Veterans Affairs Medical Center, University of Washington, Seattle, U...
Gespeichert in:
Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2000-09, Vol.49 (9), p.1477-1484 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat
islet cells.
C B Verchere ,
D A D'Alessio ,
R L Prigeon ,
R L Hull and
S E Kahn
Department of Medicine, Veterans Affairs Medical Center, University of Washington, Seattle, USA. verchere@interchange.ubc.ca
Abstract
Islet amyloid polypeptide (IAPP or amylin) is a normal secretory product of the pancreatic beta-cell that is cosecreted with
insulin and is the major constituent of islet amyloid deposits in individuals with type 2 diabetes or insulinomas. We have
previously reported that glucose stimulates IAPP, but not insulin secretion, from neonatal rat beta-cells when regulated secretion
is prevented by use of calcium-free media, suggesting that IAPP secretion occurs via a constitutive secretory pathway. To
directly test this hypothesis, we examined the effects of 2 substances-brefeldin A (BFA) and cycloheximide (CHX)-that are
predicted to selectively block constitutive secretion on the release of IAPP-like immunoreactivity (IAPP-LI) and immunoreactive
insulin (IRI) from neonatal rat islet cell monolayer cultures. When regulated release was prevented by use of calcium-free
media, glucose-stimulated IAPP-LI release was nearly abolished by blocking constitutive release with 10 microg/ml BFA (mean
+/- SD: 8.7 +/- 7.7 vs. 29.3 +/- 14.3 pmol/l; n = 5; P < 0.05), an inhibitor of constitutive vesicle formation. Similarly,
calcium-independent, glucose-stimulated IAPP-LI secretion was markedly suppressed when new protein synthesis was blocked by
administration of 20 microg/ml CHX (4.6 +/- 2.1 vs. 29.5 +/- 14.0 pmol/l; n = 5; P < 0.005). Secretion of IRI was low in the
absence of calcium, and neither BFA nor CHX had any further effect. When calcium was added to the incubation media to allow
regulated secretion of both IRI and IAPP-LI, both BFA (47.7 micro 8.7 vs. 80.7 micro 10.3 pmol/l; P < 0.001) and CHX (37.3
+/- 5.8 vs. 73.3 +/- 6.2 pmol/l; n = 5; P < 0.0001) inhibited glucose-stimulated IAPP-LI secretion by approximately 40%, but
again had no inhibitory effect on IRI secretion. These data indicate that approximately 40% of glucose-stimulated IAPP-LI
release occurs via a constitutive secretory pathway in neonatal rat islet cells. By contrast, in adult rat islets, glucose-stimulated
IAPP-LI release was almost abolished in the absence of calcium (86 +/- 3% inhibition; P < 0.05) and unaffected by addition
of BFA (275 +/- 28 vs. 205 +/- 89 pmol/l; N |
---|---|
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/diabetes.49.9.1477 |